Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Immunotherapy in Hepatocellular Carcinoma
  • CME

Credits Available
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: October 26, 2020 Expiration: October 25, 2021
Start Activity
Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
AstraZeneca
Ghassan K. Abou-Alfa, MD, MBA
Program Director
Peter R. Galle, MD, PhD
Bruno Sangro, MD, PhD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Identify patients with HCC most likely to benefit from immune checkpoint inhibitor–based combination therapy based on tumor characteristics, previous treatment, and patient characteristics and preferences
  • Evaluate clinical data on the use of immune checkpoint inhibitor–based treatment approaches for patients with early or intermediate-stage HCC
  • Plan optimal, individualized therapy approaches using immune checkpoint inhibitor–based regimens for patients with advanced or metastatic HCC, as clinically appropriate
  • Develop strategies to identify and mitigate unique adverse events associated with immune checkpoint inhibitor therapy in patients with HCC

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director

Ghassan K. Abou-Alfa, MD, MBA

Attending Physician
Memorial Sloan Kettering Cancer Center
New York, New York

Ghassan Abou-Alfa, MD, MBA, has disclosed that he and/or his spouse have received consulting fees from Aduro, Agios, Array, Aslan, AstellasPharma US, Bayer, Blueprint Medicines, Boston Scientific, Bristol-Myers Squibb, Celgene, CASI, Celsion, Delcath, Eisai, EMD Serono, Gilead Sciences, Halozyme, IntegraGen, Ipsen, Janssen, Merck, Merrimack, Momenta, New B Innovation, NewLinkGenetics, Onxeo, Opsona, Pfizer, Roche, sanofi-aventis, Servier, Silenseed, Sillajen, Sirtex, Vaxxim, Vicus, and Westhaven; and funds for research support from Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, CASI, Celgene, Chugai, Exelixis, Genentech, Incyte, Lilly, MabVax, MedImmune, Momenta, Myriad Genetics, OncoMed, Polaris, Roche, and Vicus.

Faculty

Peter R. Galle, MD, PhD

Chairman
First Department of Internal Medicine
University Medical Center
Mainz, Germany

Peter Galle, MD, PhD, has disclosed he has received consulting fees from Adaptimmune, AstraZeneca, Bayer, Bristol-Myers Squibb, Ipsen, Lilly, MSD, Roche, and Sirtex.
Bruno Sangro, MD, PhD

Professor of Medicine
Head

Liver Unit and HPB Oncology Area
Universidad de Navarra
Pamplona, Spain

Bruno Sangro, MD, PhD, has disclosed that he has received consulting fees from Adaptimmune, AstraZeneca, Bayer, Bristol Myers Squibb, Ipsen, Lilly, Roche, and Sirtex, funds for research from Bristol Myers Squibb and Sirtex, and fees for non-CME/CE services from AstraZeneca, Bayer, Bristol Myers Squibb, Ipsen, Lilly, and Sirtex.

Staff

Justine Stanley

Editorial Contributor

Justine Stanley has no relevant conflicts of interest to report.
Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy Quill, PhD, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
Katie Eustace, MBA

Senior Director, Global Medical Education, Europe

Katie Eustace, MBA, has no relevant conflicts of interest to report.
Tina B. Stacy, PharmD, FACEHP, BCOP, CHCP

Executive Vice President, Educational Strategy
General Manager, Oncology

Tina B. Stacy, PharmD, FACEHP, BCOP, CHCP, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for global medical oncologists, hepatologists, and other healthcare providers who care for patients with HCC.

Goal

The goal of this activity is to improve the knowledge and competence of learners to integrate currently available and emerging immune checkpoint inhibitor–based therapies for treatment of HCC. 

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 26, 2020, through October 25, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Immunotherapy in Hepatocellular Carcinoma
  • CME

Meet the European experts leading this activity and learn how they use ICIs and manage immune-related adverse events to optimally manage patients with previously treated HCC.

Ghassan K. Abou-Alfa, MD, MBA
Program Director
Peter R. Galle, MD, PhD
Bruno Sangro, MD, PhD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: October 26, 2020 Expiration: October 25, 2021

This program is divided into several short segments which you can step through using the Video Chapters menu.
PreviousNext

Related Content

From Clinical Care Options (CCO), watch video featuring expert perspectives on the use of immunotherapy for HCC

Lipika Goyal, MD Amit G. Singal, MD, MS Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: November 24, 2020 Expired: November 23, 2021

Commentary by Heather McArthur, MD: clinical implications of FDA approval for pembrolizumab plus chemotherapy in PD-L1–positive advanced TNBC from CCO

Heather McArthur, MD, MPH Released: November 20, 2020

Matthew Galsky, MD, discusses the evolving use of immunotherapy in urothelial carcinoma, from Clinical Care Options (CCO)

Matthew Galsky, MD Released: November 19, 2020

In slides from Clinical Care Options (CCO), experts provide insights on the optimal treatment of advanced HCC

Mark Yarchoan, MD Released: November 19, 2020

Video Chapters


Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
AstraZeneca

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue